Skip to content
Review Open access

Macrophages in T cell-mediated rejection of renal allografts: pathological mechanisms and CAR-macrophage immunotherapy

Nov 2026 · Renal Failure · Vol 48 · 0 citations · 46 references
Medicine

Abstract

Abstract Acute T cell-mediated rejection (TCMR) remains an important cause of early and intermediate-term graft dysfunction after kidney transplantation. As effector cells that bridge innate and adaptive immunity, macrophages are deeply implicated in the initiation, progression, and fibrotic sequelae of TCMR. This review synthesizes their multifaceted pathological roles: antigen presentation and T cell activation during early rejection, pro-inflammatory polarization driving parenchymal injury, chemokine-mediated recruitment that sustains immune infiltration, and macrophage-to-myofibroblast transition (MMT) underlying interstitial fibrosis in chronic graft deterioration. Because conventional immunosuppression is systemic and incompletely addresses the intragraft immune microenvironment, we further examine chimeric antigen receptor macrophages (CAR-Ms) as an emerging strategy for TCMR intervention. Building on current mechanistic insight, we propose two engineering approaches: targeted-elimination CAR-Ms designed to recognize and clear pathogenic effector immune cells, and tolerance-inducing resident CAR-Ms engineered to suppress inflammation and fibrosis while promoting tolerance. Together, these macrophage-engineering strategies provide a conceptual approach to reshaping the renal allograft immune microenvironment and improving long-term graft survival.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.